Jakafi ruxolitinib regulatory update

Incyte disclosed in its 3Q12 earnings that FDA granted Fast Track designation to ruxolitinib to treat patients with polycythemia vera (PV) who are resistant to or intolerant of hydroxyurea. The produc...